SONN
Sonnet BioTherapeutics
SONN
SONN
Delisted
SONN was delisted on the 2nd of December, 2025.
28 hedge funds and large institutions have $97.1M invested in Sonnet BioTherapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
Holders
28
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$93.6M | |
| 2 | +$687K | |
| 3 | +$441K | |
| 4 |
HF
HRT Financial
New York
|
+$340K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$258K |
Top Sellers
| 1 | -$166K | |
| 2 | -$29.2K | |
| 3 | -$16.9K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.9K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$7 |
